Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoDyn has completed the production of an adequate amount of CytoFeline to allow CytoDyn Veterinary Medicine (CVM) to move forward with next stage of research.
Subscribe to our email newsletter
CytoFeline is a monoclonal antibody developed for the treatment of Feline Immunodeficiency Virus (FIV).
Up on the completion of antibody purification, CVM will determine the practicality of anti-LFA1 antibodies to lower viral loads in FIV-infected cats, by performing in vivo efficacy tests.
CytoDyn president and chief executive officer Kenneth Van Ness said, "CVM looks forward to being able to commence the next stage of research of CytoFeline, and to continue to explore the FIV model as a potential stand-alone business opportunity."
The initial CytoFeline research was performed in the laboratory of John Elder Professor in the Department of Immunology and Microbial Science at The Scripps Research Institute.
CVM has selected Colorado State University and Susan VandeWoude, DVM, Associate Dean for Research CVMBS, Professor of Comparative Medicine, DMIP, at Colorado State University to continue the research.